Status:

ACTIVE_NOT_RECRUITING

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

Lead Sponsor:

McGill University Health Centre/Research Institute of the McGill University Health Centre

Collaborating Sponsors:

Montreal Heart Institute

Conditions:

Atrial Fibrillation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The objective of this study is to compare the efficacy of three different ablation strategies in patients with persistent AF: 1. PV antral isolation alone (PVAI) 2. PV antral isolation plus ablation ...

Eligibility Criteria

Inclusion

  • Patients 18 years of age or older
  • Patients undergoing first-time ablation procedure for AF
  • Patients with persistent AF defined as a sustained episode more than 3 months but less than three years
  • Patients with symptomatic AF - symptomatic patients are those who have been aware of their AF at any time within the last 5 years prior to enrolment. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms or any combination of the above
  • Patients whose AF has been refractory to at least one antiarrhythmic drug
  • At least one episode of AF must have been documented by ECG, holter, loop recorder, telemetry, trans-telephonic monitor or implanted device within the last 2 years from enrolment
  • Patients must be able and willing to provide written informed consent to participate in the study

Exclusion

  • Patients with paroxysmal AF (no episodes lasting \> 7 days)
  • Patients with early persistent AF, sustained episode ≤ 3 months
  • Patients with very long lasting persistent AF (episodes lasting \> 3 years)
  • Patients with CHA2DS2-VASc score of 0.
  • Patients for whom cardioversion or sinus rhythm will never be attempted/pursued
  • Patients with AF felt to be secondary to an obvious reversible cause
  • Patients with contraindication to oral anticoagulation or systemic anticoagulation with heparin
  • Patients with left atrial diameter \> 60 mm in the parasternal long axis view
  • Patients who are pregnant

Key Trial Info

Start Date :

June 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2027

Estimated Enrollment :

617 Patients enrolled

Trial Details

Trial ID

NCT04428944

Start Date

June 1 2021

End Date

December 1 2027

Last Update

February 6 2025

Active Locations (32)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (32 locations)

1

Brigham & Women'S Hosptial Inc.

Boston, Massachusetts, United States, 02115

2

Canberra Heart Rhythm Foundation

Garran, Australian Capital Territory, Australia

3

Royal Adelaide Hospital and Cardiovascular Centre

Adelaide, Australia

4

Alfred Health

Melbourne, Australia